1. CDC. Shingles (herpes zoster). www.cdc.gov/shingles/hcp/clinical-overview.html. Accessed June 26, 2013.
2. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA . 2011;305:160-166.
3. Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol . 2007;57:S130-S135.
4. Kennedy PG, Cohrs RJ. Varicella-zoster virus human ganglionic latency: a current summary. J Neurovirol . 2010;16:411-418.
5. Wilson DD. Herpes zoster: prevention, diagnosis and treatment. Nurse Pract . 2007;32:19-24.
6. Chen TM, George S, Woodruff CA, Hsu S. Clinical manifestations of varicella-zoster virus infection. Dermatol Clin . 2002;20:267-282.
7. Gilden D, Mahalingam R, Nagel MA, et al. Review: the neurobiology of varicella zoster virus infection. Neuropathol Appl Neurobiol . 2011;37:441-463.
8. CDC. Chickenpox (varicella): monitoring the impact of varicella vaccination. www.cdc.gov/chickenpox/hcp/monitoring-varicella.html. Accessed June 26, 2013.
9. Civen R, Chaves SS, Jumaan A, et all. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J . 2009;28:954-959.
10. Hardy I, Gershon AA, Steinberg SP, LaRussa P; Varicella Vaccine Collaborative Study Group. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med . 1991;325:1545-1550.
11. Poletti P, Melegaro A, Ajelli M, et al. Perspectives on the impact of varicella immunization on herpes zoster: a model-based evaluation from three European countries. PLoS One . 2013;8:e60732.
12. Goldman GS, King PG. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine . 2013;31:1680-1694.
13. Leung J, Harpaz R, Molinari NA, et al. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis . 2011;52:332-340.
14. Donahue JG, Kieke BA, Gargiullo PM, et al. Herpes zoster and exposure to the varicella zoster virus in an era of varicella vaccination. Am J Public Health . 2010;100:1116-1122.
15. Schmader KE, Oxman MN. Varicella and herpes zoster. In: Goldsmith LA, Katz SI, Gilchrest BA, et al, eds. Fitzpatrick’s Dermatology in General Medicine . 8th ed. New York, NY: McGraw-Hill; 2012.
16. Wilson JF. Herpes zoster. Ann Intern Med . 2011;154:ITC31-ITC15.
17. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep . 2008;57(RR-5):1-30.
18. Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med . 2002; 347:340-346.
19. Sauerbrei A, Eichhorn U, Schacke M, Wutzler P. Laboratory diagnosis of herpes zoster. J Clin Virol . 1999;14:31-36.
20. Whitley RJ. A 70-year-old woman with shingles. JAMA . 2009;302:73-80.
21. Galluzzi KE. Managing herpes zoster and postherpetic neuralgia. J Am Osteopath Assoc . 2009;109(6 suppl 2):S7-S12.
22. Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician . 2011;83:1432-1437.
23. Tyring S, Barbarash RA, Nahlik JE, et al; Collaborative Famciclovir Herpes Zoster Study Group. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med . 1995;123:89-96.
24. Pavan-Langston D. Herpes zoster: antivirals and pain management. Ophthalmology . 2008;115(2 suppl):S13-S20.
25. Opstelten W, Eekhof J, Neven AK, Verheij T. Treatment of herpes zoster. Can Fam Physician . 2008;54:373-377.
26. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med . 2000;9: 863-869.
27. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol . 2004;29:248-253.
28. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis . 2007;44(suppl 1):S1-S26.
29. Benbernou A, Drolet M, Levin MJ, et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain . 2011;15:1100-1106.
30. Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol . 2013;14:77-85.
31.
Whitley RJ, Weiss H, Gnann JW Jr, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med . 1996;125:376-383.
32. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med . 1994;330:896-900.
33. Wareham DW, Breuer J. Herpes zoster. BMJ . 2007;334:1211–1215.
34. Chen N, Yang M, He L, et al. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev . 2010;(12):CD005582.
35. Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician . 2002;66:1723-1730.
36. Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry . 2001;71:149-154.
37. Tilki HE, Mutluer N, Selçuki D, Stålberg E. Zoster paresis. Electromyogr Clin Neurophysiol . 2003;43:231-234.
38. Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med . 2005;352:2271-2284.
39. Opstelten W, Zuithoff NP, van Essen GA, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain . 2007;132(suppl 1):S52-S59.
40. Mahamud A, Marin M, Nickell SP, et al. Herpes zoster-related deaths in the United States: validity of death certificates and mortality rates, 1979-2007. Clin Infect Dis . 2012;55:960-6.
41. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep . 2007;56(RR-4):1-40.
42. Zostavax® (zoster vaccine live). Highlights of prescribing information (2013). www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf. Accessed June 26, 2013.
43. CDC. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep . 2011;60:1528.
44. Simberkoff MS, Arbeit RD, Johnson GR, et al; Shingles Prevention Study Group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med . 2010;152:545-554.
45. Levin MJ, Oxman MN, Zhang JH, et al; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis . 2008;197:825-835.
46. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis . 2012;55:1320-1328.
47. Singh A, Englund K. Q: Who should receive the shingles vaccine? Cleveland Clin J Med . 2009;76:45-48.
48. Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine . 2010;28:4204-4209.
